Michael Yang
Director/Board Member bei PACIRA BIOSCIENCES, INC.
Vermögen: - $ am 31.03.2024
Profil
Michael J.
Yang is currently a Director at Ionis Pharmaceuticals, Inc. and an Independent Director at Pacira Biosciences, Inc. He previously served as President, Chief Executive Officer & Director at ViaCyte, Inc., Director at Akcea Therapeutics, Inc., President at Johnson & Johnson, Chief Commercial Officer & Executive VP at ACADIA Pharmaceuticals, Inc., Vice President-Sales & Marketing at Ortho Biotech, Inc., General Manager at Veridex LLC, General Manager at Therakos, Inc., and President at Janssen Biotech, Inc. Yang received his undergraduate degree from San Diego State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PACIRA BIOSCIENCES, INC.
-.--% | 15.04.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Michael Yang
| Unternehmen | Position | Beginn |
|---|---|---|
| PACIRA BIOSCIENCES, INC. | Director/Board Member | 10.10.2023 |
| IONIS PHARMACEUTICALS, INC. | Director/Board Member | 14.12.2023 |
Ehemalige bekannte Positionen von Michael Yang
| Unternehmen | Position | Ende |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 29.01.2021 |
| AKCEA THERAPEUTICS, INC. | Director/Board Member | 12.10.2020 |
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Chief Executive Officer | - |
| JOHNSON & JOHNSON | President | - |
| Ortho Biotech, Inc. | Sales & Marketing | - |
Ausbildung von Michael Yang
| San Diego State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| PACIRA BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
| Ortho Biotech, Inc. | |
Veridex LLC
 Veridex LLC Medical SpecialtiesHealth Technology Part of Kenvue, Inc., Veridex LLC is a private company that supplies vitro diagnostic oncology products. The company is based in Raritan, NJ. | Health Technology |
Therakos, Inc.
 Therakos, Inc. Medical/Nursing ServicesHealth Services Therakos, Inc. develops immune cell therapies delivered through extracorporeal photopheresis. The firm’s engineers, clinicians and biological researchers have been driven to discover new technologies and therapeutic applications that empower the immune response and improve patient outcomes. It supports clinicians by providing products and training to enhance the treatment of cutaneous T-cell lymphoma (CTCL) and by pursuing additional approved indications for autologous immune cell therapy. The company was founded in 1984 and is headquartered in West Chester, PA. | Health Services |
Janssen Biotech, Inc.
 Janssen Biotech, Inc. Pharmaceuticals: MajorHealth Technology Janssen Biotech, Inc. engages in the development and marketing of prescription drugs. The company is headquartered in Horsham, PA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
